Several cytisine derivatives have been developed in the search for more selective drugs at nicotinic acetylcholine receptors (nAChR). Binding experiments in transfected cell lines showed that the iodination of cytisine in the position 3 of the pyridone ring increased potency at a7-nAChR and to a lesser extent at the a4b2 subtypes, both of which are widely expressed in the brain. However, no in vivo studies have been published on this compound. Inhibition curves presented here using wild type, b2, and b4-null mutant mice confirm that 3-IC binds to a4b2*, a7* and a3b4* receptors with higher affinity than cytisine (asterisk indicates the receptor may contain additional subunits, Lukas et al., 1999) . Intraperitoneal injection of 3-iodocytisine (3-IC) induced considerable dose-dependent hypothermia in DBA/2J and C57BL/6J mice. This response was blocked by mecamylamine and partially inhibited by hexamethonium.
I]epibatidine sites were unchanged. [ 125 I]a-Bungarotoxin binding sites also exhibited up-regulation. These results give a first evaluation of in vivo consequences of 3-IC as a potent agonist with marked effects on mice.
Ó 2009 Elsevier Ltd. All rights reserved.
Introduction
Nicotinic acetylcholine receptors (nAChR) constitute a family of ligand-gated ion channels assembled in neurons as pentameric receptors. While mRNA encoding nine nAChR subunits (a2-a7 and b2-b4) is expressed in mammalian brain, the major neuronal subtypes in the central nervous system are homomeric a7*-nAChR and heteromeric a4b2*-nAChR (Dani and Bertrand, 2007) . nAChR mediate several simple and complex behavioral and physiological responses (Picciotto, 2003) . nAChR also mediates short-term and long-term responses to nicotine and similar drugs indicating a role in nicotine tolerance and dependence (Dani and DeBiasi, 2001) . nAChRs have also been implicated in several human neurological and psychiatric disorders. Single point mutations in either the a4 or b2 nAChR subunits have been identified as the cause of several different Autosomal Dominant Nocturnal Frontal Lobe Epilepsies (Hogg and Bertrand, 2004) . Although the evidence is not as obvious, nAChR also appear to be involved in the etiology of Alzheimer's and Parkinson's diseases as well as in psychopathologies such as anxiety disorders, Tourette's syndrome and schizophrenia (Bourin et al., 2003; Leonard et al., 2001) . Because of the relevance of nicotinic physiology to health issues, nAChR ligands are envisioned as potential therapeutic agents for Parkinson's disease (Quik, 2004) , obsessive-compulsive disorder (Salin-Pascual and Basanez-Villa, 2003) and schizophrenia (Harris et al., 2004) .
Specific and potent nicotinic ligands would facilitate investigation of the multiplicity of in vivo effects modulated by nAChR.
Cytisine is a plant alkaloid with higher affinity for neural a4b2-nAChR than nicotine (Pabreza et al., 1991) . It is a partial agonist at b2*-nAChR but a full agonist at b4*-nAChR (Luetje and Patrick, 1991) . Due to its semi-rigid structure cytisine has been used as a template for the preparation of new nicotinic receptor ligands. A group of cytisine derivatives has, indeed, been developed (Imming et al., 2001; Slater et al., 2003) . Varenicline, which has recently been approved for smoking cessation, is such an analog (Lam and Patel, 2007 ). An electrophysiological characterization of the effects of cytisine and its bromo derivatives, in particular 3-bromocytisine, showed a potent effect on inward currents in ACh-activated neurons in cat petrosal ganglion neurons in culture (Varas et al., 2006) . The C3-halogenated derivatives of cytisine, and particularly 3-iodocytisine (3-IC) display higher binding affinity than cytisine determined either a7* and a4b2* receptors in rat brain with K i values of 115 nM and 0.17 nM compared to 8 mM and 1.2 nM, respectively (Abin-Carriquiry et al., 2006) . Similarly, for human a7 and a4b2 expressed in Xenopus oocytes 3-IC has K i values of 7.0 and 0.7 nM compared to 30 mM and 0.6 nM for cytisine respectively (Slater et al., 2003) . 3-IC is also more potent that cytisine in stimulating [ 3 H]noradrenaline release from rat hippocampal slices and for values of 0.22 mM and 0.011 mM for 3-IC compared to 7.4 mM and 0.28 mM for cytisine, respectively (Abin-Carriquiry et al., 2006) . Similarly, in Xenopus oocytes expressing human a7-nAChR, the EC 50 value for 3-IC was 1.5 mM, compared to 83 mM for cytisine, while EC 50 values for the high and low agonist sensitive forms of a4b2-nAChR were 0.8 nM and 86 nM for 3-IC and 5 nM and 2 mM for cytisine (Slater et al., 2003; Abin-Carriquiry et al., 2006) . Beyond these in vitro analyses, 3-IC has never been tested in an in vivo model. Here, we describe the acute effect of 3-IC in the modulation of body temperature in mice including evaluation of the effect of some nicotinic antagonists and deletion of either the a7, b2 or b4 nAChR genes on the hypothermic response. Finally we expand the effect of chronic 3-IC treatment on nAChR binding sites in mouse brain. 
Materials

Methods
Synthesis of 3-IC
Cytisine was purified from Sophora secundiflora seeds using standard methodology. Monohalogenated cytisine derivatives were prepared by treating cytisine with iodine monochloride. The iodinated isomers were separated by column chromatography on silica gel, crystallized to homogeneity and characterized by 1 H and 13 C NMR and HREIMS as reported before (Slater et al., 2003) .
Mice
DBA/2J and C57BL/6J mice were bred at the Institute for Behavioral Genetics, University of Colorado, Boulder, CO and housed five per cage prior to testing or surgery and chronic nicotine treatment.
a7
À/À (Orr-Urtreger et al., 1997), b2 À/À (Picciotto et al., 1995) and b4 À/À (Xu et al., 1999) and wild-type littermates were generated by mating heterozygotes for each mutation. Each of these null mutant mice has been backcrossed with C57BL/6JJ mice for at least 10 generations at the time of the experiments. Mice were weaned at 25 days of age and housed with like-sexed littermates. DNA was extracted from tail clippings obtained from 40-day old mice and genotypes were determined as described previously (Salminen et al., 2004) . Mice were allowed free access to food (Rodent Chow, Harlan-Teklad, Madison, WI) and water. The animal vivarium was maintained at a temperature of 23 AE 2 C with a 12 h light/12 h dark cycle (lights on 7 AM-7 PM). All procedures used in this study were reviewed and approved by the Animal Care and Utilization Committee of the University of Colorado.
Temperature measurements
Body temperature measurement was chosen for these experiments because the hypothermic effects of nAChR ligands have been reported before for the two different mice strains used in this study (Marks et al., 1983a; Tritto et al., 2004) . DBA/2J, C57/BL6 and wild type and a7-, b2-and b4-null mutant mice were tested under similar conditions for determination of body temperature. All drugs were administered intraperitoneally (IP) (10 ml/g of body weight in every injection). All antagonists were injected 10 min before the 3-IC injections. Temperature was measured with a Thermalert rectal probe lubricated with peanut oil and inserted 1.5 cm into the mouse's rectum.
Chronic 3-IC treatment
DBA/2J mice were anesthetized with pentobarbital (45 mg/kg)-chloral hydrate (63 mg/kg). A cannula was implanted in the right jugular vein (Barr et al., 1979) and after surgery the animals were placed in individual cages (15 Â 15 Â 25 cm). Following 2 days of continuous saline infusion (35 ml/h), treatment with 3-IC was begun. Fresh drug and saline solution was supplied every day. Mice were randomly assigned to two groups: saline infused (control) or 3-IC 0.2 mg/kg/h. Stock 3-IC solutions (10 mg/ml) were prepared in sterile saline, neutralized with HCl and stored in the dark at 4 C. Dilutions of this stock solution were prepared to give the appropriate hourly dose. Mice were subsequently infused with 3-IC for 7 days. Following the 7-day treatment, infusion was terminated. Two hours after ending treatment mice were injected IP with 0.2 mg/kg 3-IC and body temperature was measured at 5-min intervals for the first 20 min and at 10 min intervals thereafter.
Membrane preparation
Two hours following completion of the tolerance test (5 h after withdrawal from drug infusion), mice that had been treated chronically with saline or 0.2 mg/kg/h 3-IC were killed by cervical dislocation. Each brain was placed on an ice-cold platform and dissected into the following brain regions: cerebral cortex (Cx), striatum (St), hippocampus (Hp), thalamus (Th), superior colliculus (SC), inferior colliculus (IC) and midbrain (MB). Each brain region was homogenized in ice-cold hypotonic buffer (NaCl, 14.4 mM; KCl, 0.2 mM; CaCl 2 , 0.2 mM; MgSO 4 , 0.1 mM; HEPES 2 mM; pH ¼ 7.5) using a Teflon-glass tissue grinder. The particulate fractions were obtained by centrifugation at 20,000 Â g (10 min, 4 C; Sorvall RC-2B centrifuge). The pellets were resuspended in fresh homogenization buffer and washed four times by resuspension/centrifugation, and stored (in pellet form under homogenization buffer) at À70 C until used. (Whiteaker et al., 2000) . Frozen, washed pellets were resuspended in the overlying buffer and centrifuged at 20,000 Â g for 20 min. The supernatant was discarded and the pellet was resuspended in ice-cold water. cytisine-sensitive (primarily a4b2*), cytisine-resistant (mixed population), A85380-sensitive (b2*-nAChR), and A85380-resistant (b4*-nAChR) (Whiteaker et al., 2000 An incubation volume of 30 ml was used. Nine concentrations of drugs (1 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1 mM, 3 mM, 10 mM and 100 mM) were used. Blanks were established by measuring binding in the presence of 1 mM nicotine.
Protein determination
Protein was measured according to the method of Lowry et al. (1951) using bovine serum albumin as the standard.
Data calculations
Results of the maximal drop in temperature in the acute dose response experiments were analyzed using the following four parameter logistic equation to obtain estimates of ED 50 values;
, where Y is the response after each treatment with each dose of 3-IC, min is the change in temperature after saline treatment, max is the change in temperature observed at the highest dose of 3-IC, X is dose of 3-IC, ED 50 is 3-IC dose eliciting 50% of the maximal response and N correspond to the Hill coefficient.
[
]Epibatidine binding site densities inhibited by cytisine and A85380 were calculated using a two-site inhibition model: 
Autoradiography: preparation of sections
Autoradiographic procedures were similar to those described previously (Whiteaker et al., 2000) . At the completion of the chronic treatment DBA/2J mice were killed by cervical dislocation, the brains were removed from the skulls and rapidly frozen by immersion in isopentane (À20 C, 10 s). The frozen brains were wrapped in aluminium foil, packed in ice, and stored at À70 C until sectioning. Tissue sections 14 mm thick prepared using a Leica Model 1850 cryostat refrigerated to À16 C were thaw-mounted onto Superfrost Ò /plus microscope slides (Fisher Scientific). Mounted sections were stored, desiccated, at À70 C until use. Ten series of sections were collected from each mouse brain. 
Autoradiography: image collection
Following the wash, labelled sections were dried with a stream of air and stored overnight at 22 C under vacuum. Mounted, desiccated sections were apposed to super resolution Cyclone storage phosphor screens (Perkin-Elmer, Shelton, CT) for 2-5 days. Images were captured with a Cyclone phosphorimaging instrument forquantitative analysis of signal intensity by comparison with commercial 125 I standards (GE Healthcare, Piscataway, NJ). Signal intensity of selected regions was determined by using Cyclone software. When it was possible, six independent measurements from different tissue sections were made for each brain region, under each incubation condition, for each mouse. The pixel density for each brain area was averaged, and the mean signal was used to calculate the degree of labelling by reference to the relevant standard curve. Higher resolution images were obtained by exposure of the slides to Kodak MR film for 3-10 days. After the films had been exposed to the sections for an appropriate length of time, they were developed and autoradiographic images of the sections were photographed using a Canon D40 digital camera.
3.14. Statistical analyses of data SPSS software was used for the statistical analysis of data. Effects of 3-IC on body temperature were analyzed using repeated measures ANOVA with time and treatments as within-subjects' variables and between-subjects' factors for the analysis of the dose-response curves, respectively. Effects of nicotinic receptor null mutations were also analyzed using repeated measures ANOVAs with time and genotype as the within-subjects variable and between-subjects factor, respectively. The maximal temperature decrease for each treatment and variations in nAChR binding sites in saline and 3-IC chronically treated mice and values of binding assays for saline or 3-IC treated animals were also analyzed using the unpaired Student test. Statistical significance was assumed for p values < 0.05. All data are presented as mean AE SEM.
Results
Dose dependency of 3-IC-induced hypothermia
To elucidate the effect of 3-IC on thermoregulation, wild-type DBA/2J and C57BL/6J mice were injected intraperitoneally with 0.05, 0.1, 0.2, 0.5 and 1 mg/kg of the drug. Rectal temperature was measured at 5 min intervals through the first 20 min and at 10 min intervals thereafter. A statistically significant effect of dose and time on hypothermic effect following 3-IC injections was observed for both mice strains (Fig. 1A , C, p < 0.001 for time variable, p < 0.001 for dose factor in DBA/2J and C57BL/6J). The significant time by dose interaction (p < 0.001 for both mice strains) confirmed that the time course for hypothermia varied with dose. A dose-dependent increase in magnitude and persistence of hypothermia was observed following administration of 3-IC. Doses of 0.05 and 0.1 mg/kg elicited modest temperature decreases that rapidly recovered. The extent and duration of hypothermia were observed for doses of 0.2 mg/kg and higher and was much longer than that observed for lower doses. The maximal temperature decrease elicited with 1 mg/kg 3-IC (the highest dose tested) was 11.9 AE 0.4 C in DBA/2J and 13.3 AE 0.9 C in C57BL/6J (Fig. 1 ). Tremors were seen at doses above 0.5 mg/kg. No statistical difference was observed for an acute injection of 3-IC at 0.2 mg/kg dose in DBA/2J and C57BL/6J mice, producing a decrease of basal temperature of 7.7 AE 0.5 C and 9.2 AE 1.13 C respectively (Fig. 1) . This dose was chosen for further experiments because a clear effect on temperature was observed, without inducing tremors or diarrhea. Despite the remarkable effect of 3-IC on temperature, no seizures were noted at any dose tested. Both mouse strains had similar sensitivity to 3-IC with ED 50 values of 0.15 AE 0.04 mg/kg for DBA/2J and 0.16 AE 0.03 mg/kg for C57BL/6J mice. A modest temperature increase was observed at approximately 20 min following saline injection (0.67 AE 0.09 C for DBA/2J and 0.17 AE 0.03 C for C57BL/6J).
Hypothermia produced by 3-IC requires nicotinic receptor activation
To explore the specific role of nicotinic receptors in the modulation of mouse body temperature induced by 3-IC, the nicotinic antagonist mecamylamine was injected 10 min before 3-IC injections. A statistically significant difference was obtained for both, the time variable and mecamylamine treatment factor (p < 0.001; p < 0.001 respectively). DBA/2J and C57BL/6J mice pretreated with mecamylamine (1 mg/kg) displayed much less hypothermia (1.13 AE 0.42 C and 0.13 AE 0.09 C respectively) than did mice pretreated with saline (8.50 AE 0.42 C and 9.25 AE 0.76 C respectively) (Fig. 2C) . For DBA/2J mice following mecamylamine treatment, maximal hypothermia was observed 20 min after 3-IC injection while maximal hypothermia following saline pretreated was observed 40 min after 3-IC injection ( Fig. 2A) . The blockade of 3-IC-induced hypothermia in C57BL/6J mice was complete, that is, no temperature decrease was noted at any time (Fig. 2B) . The 1 mg/kg mecamylamine dose did not affect body temperature in both mice strains (Fig. 1A-C) .
The possible contribution of muscarinic acetylcholine receptors to the hypothermic effect of 3-IC was tested in mice injected with scopolamine (10 mg/kg), a non-specific muscarinic antagonist, 10 min before the injection with 3-IC (0.2 mg/kg). No difference in maximal decrease or time course of 3-IC-induced hypothermia was observed between mice of either strain treated with saline or scopolamine (Fig. 2H-J) .
Central and peripheral nervous system-controlled 3-IC-induced hypothermia
The role of the peripheral nAChR in mediating 3-IC-induced hypothermia was also evaluated by using the nicotinic antagonist hexamethonium (HXMT), which has a very low penetration to the brain-blood barrier. Mice were injected with 10 mg/kg HXMT 10 min before 3-IC (0.2 mg/kg) and rectal temperature was recorded. Injection of 10 mg/kg HXMT did not affect body temperature in C57BL/6J mice compared to saline injected mice, however DBA/2J mice showed a modest, but statistically significant, hypothermia compared to saline injected mice ( Fig. 1A and C ; p < 0.05, comparison of maximal change in temperature). A statistically significant inhibition of maximal 3-ICinduced hypothermia was observed for mice pretreated with hexamethonium (10 mg/kg) compared to those pretreated with saline (for DBA/2J: 5.66 AE 0.45 C and 8.10 AE 0.63 , and for C57BL/6J: 3.75 AE 0.67 C and 9.25 AE 0.76 C, respectively) (Fig. 2F , *p < 0.05) and also they recovered more rapidly from the hypothermia than did saline-treated mice, which is supported by the statistical analysis in the time by treatment interaction for both mice strains with p values < 0.001 for DBA/2J and <0.007 for C57BL/6J ( Fig. 2D and E) . The blockade of 3-IC-induced hypothermia was more profound in C57BL/6J than DBA/2J, where a 60% and 33% of the maximal effect was observed respectively. These results suggest the participation of peripheral nAChR in hypothermia induced by 3-IC administration and that the peripheral effects of 3-IC may be more profound for C57BL/6J mice.
Role of specific nicotinic subunits in 3-IC-induced hypothermia
The results presented above established that the actions of 3-IC are mediated by nAChR and that a significant fraction of this effect appears to be mediated by peripheral nAChR. In order to examine the contribution of different nAChR subtypes, 3-IC was administered to mice in which the a7, b2 or b4 nAChR subunits had been deleted. Previous reports have shown deletion of b4 (Sack et al., 2005) or b2 but not a7 (Tritto et al., 2004) subunits reduced nicotine-induced hypothermia.
Similar to the effects of a7 gene deletion on nicotine-induced hypothermia, no significant differences in maximal temperature decrease (Fig. 3B ) or in the time course for 3-IC-induced hypothermia were observed following deletion of the a7 subunit (Fig. 3A) .
A modest effect of b2 gene deletion was observed. Repeated measures ANOVA revealed a significant difference within b2-null and wild-type mice for time variable but not for the genotype factor (p < 0.001 and p ¼ 0.059, respectively). However deletion of the b2 subunit did reduce maximal 3-IC-induced hypothermia with a decrease of temperature of 8.4 AE 1 C for b2 À/À compared to 9.8 AE 0.76 C for b2 þ/þ , p < 0.05 (Fig. 3D) . b2 À/À mice appeared to recover more rapidly from 3-IC-induced hypothermia than did b2 þ/þ (Fig. 3C) . In contrast, a substantial contribution of the b4*-nAChR receptors was observed to 3-IC-induced hypothermia. Repeated measures ANOVA revealed statistically significant differences for the time variable and genotype factor between b4-null and wildtype mice (p < 0.001 and p < 0.001, respectively). A statistically significant time by genotype interaction was also found (p < 0.001). This analysis is supported by the observation of a significant decrease in maximal hypothermia for b4-null mutant mice (b4 À/À , 2.9 AE 0.4 C; b4 þ/þ , 7.9 AE 0.3 C, p < 0.05) (Fig. 3F ) and the faster recovery of basal temperature (Fig. 3E) . ]a-bungarotoxin binding sites in hippocampus of wild-type C57BL/6J mice. Cytisine inhibition in IC from wild-type mice was best fit to a two-site model. However, the biphasic nature of the inhibition curves was less obvious for nicotine and even less obvious for 3-IC as the difference in affinity between the two sites for those drugs decreased (Table 1 ). These differences in the inhibition curves for the three compounds occurred because the differences in affinity of cytisine for the two [ 125 I]epibatidine binding sites was greater (60-fold) than that for either nicotine (20-fold) or 3-IC (1.6-fold). In order to test the contribution of b2*-nAChR and b4*-nAChR to the binding patterns in wild-type mice, inhibition curves were constructed for the three compounds in IC prepared from b4 À/À and b2 (Fig. 4) a4b2*), A85380-resistant (mainly a3b4*-nAChR) and cytisineresistant minus A85380-resistant (non-a4, b2*-nAChR) [
125 I]epibatidine binding sites (Whiteaker et al., 2000; Marks et al., 2004) . The response of the cytisine-sensitive sites to chronic 3-IC treatment differed among the brain regions. Significant increases in cytisine-sensitive [ 125 I]epibatidine binding sites were only observed in cerebral cortex and hippocampus (70.3 AE 10.7% and 96.1 AE 12.1% increase compared to saline infused mice respectively), while there was a tendency for small, but insignificant, increases in binding to occur in several others brain regions (Fig. 5) .
No significant differences in the density of cytisine-resistant [ 125 I]epibatidine binding sites were observed between saline or 3-IC chronically treated mice in any brain region analyzed (Fig. 5) . The A85380-resistant component of [ 125 I]epibatidine binding was also unmodified by chronic 3-IC treatment (Fig. 3) .
125 I]a-bungarotoxin binding sites appeared to be increased by chronic 3-IC treatment in each of the three brain regions assayed although the effect only attained statistical significance in cerebral cortex detecting a 58% increase compared to saline infused mice (Fig. 6) . regulated by chronic 3-IC treatment; statistically significant increases in binding were observed in parietal cortex, hippocampus, caudate putamen, nucleus accumbens, substantia nigra, olfactory tubercle, external layer of inferior colliculus, superior colliculus and ventral tegmental area, with increases ranging from 45.2% in ventral tegmental area to 126.2% in the optic tract as compared to saline infused mice. Some brain regions (thalamic nuclei, medial habenula, fasciculus retroflexus among others) were unaffected by the chronic 3-IC treatment (Table 1) . The cytisine-resistant [ 125 I]epibatidine sites, which are found in areas such as interpeduncular nuclei, medial habenula and colliculi (Fig. 7) were not affected by chronic 3-IC treatment (Table 2) . a7*-nAChR binding sites were also analyzed by autoradiography (Fig. 7) . All regions analyzed tend to show an increase of [ 125 I]abungarotoxin binding site density after chronic 3-IC treatment that ranged from 11.1% in cingulate cortex to 81.2% in nucleus accumbens as percentage of saline infused controls (Table 3) ; statistically significant differences were found in some areas such as parietal cortex, hippocampus, caudate putamen, nucleus accumbens, substantia nigra, ventrolateral geniculate nucleus, interpeduncular nucleus and superior colliculi.
Discussion
We report here the effects of 3-IC in mice, including effect of acute doses on body temperature regulation, binding potency at major nAChR populations in brain and the modulation of those receptors after chronic drug treatment. These results are generally consistent with the previous studies of 3-IC in vitro. the hypothermia by mecamylamine and lack of effect of scopolamine established that activation of nicotinic, but not muscarinic, receptors is necessary for 3-IC-induced hypothermia. The effect of 3-IC on body temperature was dependent on the activation of both peripheral and central nAChR as determined by the partial blockade with hexamethonium. Experiments with null mutant mice indicated that the a7* receptor did not significantly mediate 3-IC-induced hypothermia, which is consistent with the observation that deletion of a7 had no effect on nicotine-induced hypothermia (Tritto et al., 2004) . Although b2 À/À mice displayed significant hypothermia following 3-IC injection, the magnitude and duration of this response was less than that of wild-type mice, suggesting some role for b2*-nAChR. A partial but more pronounced effect of b2 gene deletion was observed for nicotine-induced hypothermia (Tritto et al., 2004) . However, b4
À/À mice were much less affected by the same dose of 3-IC, indicating that activation of nAChR containing this subunit is responsible for most of the hypothermic response.
A significant contribution of b4*-nAChR in the control of body temperature agrees with a previous report performed in mice using nicotine as an agonist (Sack et al., 2005) . While the effect of 3-IC may be also associated with desensitization after receptor activation, a mechanism that is common with nAChR, a3b4*-nAChR desensitize more slowly and require higher ligand concentrations than a4b2*-nAChR (for review see Quick and Lester, 2002) . Prolonged activation of a3b4*-nAChR may contribute to the large effect of 3-IC. The assumption that the effect of 3-IC might be due the activation of a3b4*-nAChR is supported also by the observation that 3-IC is approximately 100-fold more potent as an inhibitor of [ 125 I]epibatidine binding in b2 À/À mice than cytisine or nicotine. The a3b4* receptor has been shown to be the most abundant among b4 subunit-containing nAChR expressed in autonomic ganglia (Conroy and Berg, 1995) , suggesting a role for these receptors in the hypothermic response, a result consistent with the partial sensitivity to hexamethonium. However the contribution of central b4*-nAChR cannot be completely discounted.
3-Bromocytisine is a full agonist at human a3b4-nAChR expressed in Xenopus oocytes, being more potent than either acetylcholine or cytisine (Abin-Carriquiry et al., 2006) , suggesting that 3-IC would have a similar effect on a3b4*-nAChR because both C3-halogenated compounds exhibit a similar pharmacology (Slater et al., 2003; Imming et al., 2001) . The higher potency and efficacy of 3-IC relative to cytisine can be explained by the influence of the halogen atom on the affinity of 3-IC for a4b2* and a7*-nAChR as discussed before (Slater et al., 2003) , although pharmacokinetic factors may also be involved.
The pharmacokinetic of 3-IC is not known. However, cytisine has a longer half-life than nicotine in rats (Sloan et al., 1988) . Nonetheless, further work is necessary in order to reveal pharmacokinetic parameters such as distribution, blood-brain barrier penetration, metabolism and excretion of 3-IC.
Effect of chronic 3-IC on nAChR binding sites
The up-regulation of nAChR binding sites by chronic nicotine treatment is well established (Marks et al., 1983b Flores et al., 1992; Sparks and Pauly, 1999; Nguyen et al., 2003; McCallum et al., 2006; Rasmussen and Perry, 2006) . We observed here a differential increase in a4b2*-nAChR, principally in dopaminergic brain areas, cerebral cortex and hippocampus. In contrast, A85380-resistant [ 125 I]epibatidine biding sites (likely b4*-nAChR) were unchanged after chronic 3-IC treatment. A similar insensitivity to up-regulation of b4*-nAChR following nicotine treatment has been noted for adrenal gland, superior cervical ganglion and pineal (Davila-Garcia et al., 2003) and also following nicotine treatment in mice . Perhaps, the absence of tolerance to the hypothermic effect of 3-IC observed after chronic treatment reflects the major contribution of b4*-nAChR to 3-IC-induced hypothermia and the insensitivity of b4*-nAChR to up-regulation (Nguyen et al., 2003; McCallum et al., 2006) . The pattern of binding sites observed in the autoradiography for the a7*-nAChR population is consistent with the previous reports (Pauly et al., 1989; Sparks and Pauly, 1999; Rasmussen and Perry, 2006) , showing a high density in hippocampus, caudate putamen, superior and inferior colliculus and some structures in the mesencephalon and hindbrain as well. [
125 I]a-Bungarotoxin binding sites (a7-nAChR) are less responsive to chronic nicotine treatment than are a4b2*-nAChR binding sites (Marks et al., 1983b) . The up-regulation of a7* receptors depends on the route of administration and the doses required are higher than those that elicit increase in a4b2*-nAChR (Sparks and Pauly, 1999; Rasmussen and Perry, 2006) .
The increases in [
125 I]a-bungarotoxin binding sites produced by chronic 3-IC treatment are greater than those reported in mice treated chronically with nicotine, i.e. in dentate gyrus there was an increase of 63.5% compared with the 12.6% increase detected in the same DBA/2J mice with a ten days 2 mg/kg/h nicotine treatment (Pauly et al., 1991) ; zona incerta 52.1% compared to 17.6%; hippocampus 77.5% compared to 33%; caudate putamen 65.8% compared to 14.2%. However, there were regions in these two studies that showed similar a7* up-regulation such as medial habenula 26.4% compared to 22.6%; ventral tegmental area 40.5% compared to 32.4%; substantia nigra 29.5% compared to 25.6%. The greater effect on binding sites elicited by chronic 3-IC treatment may be related to relatively high affinity of the C3 halo-derivatives of cytisine on a7* receptors (Abin-Carriquiry et al., 2006) . This postulate is supported by the observation that 3-IC is a much more potent inhibitor of [ 125 I]a-bungarotoxin binding than cytisine or nicotine. cingulated cortex (Cg), parietal cortex at superficial layers (Cx 1-3 ) and deep layers (Cx 4-6 ), retrosplenial cortex (RS), hippocampus at CA1/CA2/CA3 (Hp CA1-3 ) region and dentate gyrus granule layer (Hp DG ), caudate putamen (Cp), nucleus accumbens (NAcc), medial habenula (MH), inferior colliculi at dorsal cortex (DCIC), central nucleus (ICCN) and external cortex (ICEC), superior colliculi at superficial gray (SuG) and optic nerve (Op), fasciculus retroflexus (fr).
Concluding remarks
In the present we report an in vivo effect of 3-IC on the population of central nervous system and peripheral nAChR has been demonstrated. In the case of new drugs for smoking cessation the central effects are desired and 3-IC has profound autonomic effects. Our results indicate that 3-IC may not be the best choice for this application. However, owing to the profound hypothermia elicited, 3-IC may be useful in prevention of degenerative processes observed in nervous tissue after ischemic damage, since a decrease in core body temperature is used to mitigate damage (Olsen et al., 2003; Gordon, 2001) , however, an extensive exploration of systemic effects including pharmacological interactions with anaesthetic drugs is needed. Furthermore, 3-IC may be a useful compound for the study of the effects of activation of b4*-nAChR.
